^
Association details:
| Biomarker: | CLTC-ALK fusion |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Promising response of anaplastic lymphoma kinase-positive large B-cell lymphoma to crizotinib salvage treatment: case report and review of literature
Excerpt:
We report a case of a 21-year-old male ALK + DLBCL patient...while RT-PCR detected a CLTC-ALK fusion transcript which was confirmed by Sanger sequencing...We administered two courses of an alternative salvage chemotherapy regimen containing GEMOX and dexamethasone with the addition of the ALK inhibitor crizotinib. His symptoms alleviated for a short time but soon worsened and the patient died of massive progressive disease.
Secondary therapy:
GemOx + dexamethasone
